Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GE will acquire Abbott diagnostics ...

January 29, 2007 | A version of this story appeared in Volume 85, Issue 5

General Electric has agreed to acquire Abbott Laboratories' in vitro and point-of-care diagnostics businesses for $8.13 billion in cash. The in vitro unit tests blood or urine samples to diagnose disease. GE says the new business will complement its existing in vivo diagnostic imaging systems, which use X-ray, magnetic resonance, and ultrasound to diagnose disease. The point-of-care unit manufactures diagnostic products for blood gas and blood chemistry analysis in doctors' offices and emergency rooms. The acquisition builds on GE's 2003 purchase of Amersham, a maker of imaging agents and drug discovery tools.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.